Novartis Acquires Avidity Biosciences for $12 Billion to Advance RNA-Based Therapies

Swiss pharmaceutical company Novartis has announced the acquisition of US biotechnology company Avidity Biosciences for $12 billion. This transaction represents a decisive step in Novartis’ expansion into advanced RNA-based therapies.

San Diego-based Avidity specializes in treatments for serious genetic neuromuscular diseases. The Novartis Avidity alliance strengthens both companies’ commitment to biomedical innovation.

The acquisition of Avidity represents a decisive step in Novartis’ expansion into advanced RNA-based therapies

The acquisition will be conducted through a tender offer for $72 per share. This represents a 46% premium to the previous market value. The deal has been unanimously approved by the boards of directors of Novartis and Avidity. Prior to closing, Avidity will spin off its cardiology programs into a new company called SpinCo. Shareholders will receive one SpinCo share for every ten Avidity shares. Final closing is expected in the first half of 2026.

The Novartis Avidity transaction will allow Novartis to incorporate a highly differentiated RNA delivery platform. This technology has the potential to transform the treatment of neuromuscular diseases. It also expands Novartis’ reach in the field of neuroscience. The company expects this acquisition to drive annual revenue growth of up to 6% through 2029.

This strategy aligns with its focus on therapeutic areas with high innovation potential and unmet medical needs.

With this acquisition, Novartis positions itself as a leader in advanced RNA-based therapies.
Novartis’ acquisition of Avidity marks a milestone in the evolution of personalized medicine. With this transaction, Novartis Avidity positions itself as a leader in advanced RNA-based therapies.

The merger of the two companies promises to accelerate the development of more effective and safer treatments. This acquisition also reflects the growing importance of targeted therapies in the global pharmaceutical industry. The official Novartis press release is available here .

Novartis’s commitment to Avidity is not only driven by financial logic, but also by scientific ones. Avidity’s platform enables precise delivery of therapeutic molecules, improving efficacy and reducing adverse effects.

Novartis Avidity represents a synergy between pharmaceutical expertise and cutting-edge biotechnology. In a context of growing demand for personalized solutions, this alliance could mark the future of clinical neuroscience.

__

(Featured image by MJH SHIKDER via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.